GlassScriptPhysician profile
Saumya Shah
NPI 1770046369
$4,361.69
in general payments reported to CMS, 2019-2025
32 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $230 · 2023: $1,339 · 2024: $1,771 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,132.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,352.00 | 2022-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Abbvie INC. | $911.24 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $347.50 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $220.60 | 2022-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $198.27 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $177.25 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $166.27 | 2024 | Izervay, Veozah |
| Exact Sciences Corporation | $118.52 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.65 | 2023-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.23 | 2022-2023 | Stiolto Respimat, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $68.40 | 2022-2025 | |
| Viatris Specialty LLC | $66.26 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $54.10 | 2024-2025 | Opsumit, Uptravi |
| Amgen INC. | $47.73 | 2025 | Uplizna, Tepezza |
| Corcept Therapeutics | $45.75 | 2024-2025 | Korlym |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $43.36 | 2023-2024 | |
| Madrigal Pharmaceuticals | $38.09 | 2025 | Rezdiffra |
| Genzyme Corporation | $34.33 | 2025 | |
| Idorsia Pharmaceuticals US INC | $32.35 | 2023-2024 | Quviviq |
| Sumitomo Pharma America, INC. | $29.29 | 2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $28.26 | 2024 | |
| Mylan Specialty L.P. | $23.73 | 2024 | Yupelri |
| Bausch Health US, LLC | $22.13 | 2023 | Aplenzin, Wellbutrin |
| Amneal Pharmaceuticals LLC | $20.65 | 2025 | Unithroid |
| Amarin Pharma, INC. | $20.24 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.22 | 2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $18.96 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $18.75 | 2023 | Dupixent |
| Optinose US, INC. | $17.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.16 | 2023 | Hyqvia |
| Inspire Medical Systems, INC. | $16.25 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $13.78 | 2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saumya Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.